S. 5127, Clinical Trial Participation Incentive. Quorum's AI analysis reads it as a net benefit — and names who gains.
S. 5127 · Net good
What it does
This bill exempts compensation paid to clinical trial participants from federal income tax and excludes it from counting as income when determining eligibility for federal assistance programs (like Medicaid, SNAP, housing assistance). Participants can receive payment for their time and reimbursement for trial-related expenses without triggering tax liability or losing benefits.
The analysis names pharmaceutical companies — and 3 more groups — among the beneficiaries.
The trade-off
Pharmaceutical and biotech companies may benefit indirectly by reducing recruitment friction for trials, potentially lowering trial costs and accelerating enrollment — a private benefit not explicitly stated in the bill's civic framing.
Transparency scores 85%, with a medium warning level and no detached riders.
Who is behind it
Filed by Jim Banks. Cosponsored by Catherine Cortez Masto.